Business Wire

NY-IMPACTWAYV

9.3.2021 15:02:11 CET | Business Wire | Press release

Share
ImpactWayv™ Completes Beta Test of Its Social Impact Media and Technology Platform and Announces Upcoming Public Launch

ImpactWayv, Inc. is pleased to announce it has recently concluded the private beta test of ImpactWayv ™, the company’s pioneering social impact media and technology networking platform that will launch publicly this spring. ImpactWayv connects people, businesses and philanthropy – for good.

Designed to be a healthier and more meaningful alternative to major social networking platforms, ImpactWayv is the next generation digital ecosystem where people, businesses and nonprofits engage to effect positive change and maximize social impact. ImpactWayv unites disparate sources of information, initiatives and innovations from across the global social good sector under one digital roof to generate greater and more efficient collective impact.

Reception to ImpactWayv’s invitation-only private beta test was overwhelmingly positive, with individual, business and nonprofit users confirming the strong need for this type of holistic social impact-focused platform within today’s social media landscape. Users were guided through ImpactWayv’s core user flow to validate design, functionality and usability. The results reinforced the platform’s underlying social impact thesis, focused on fostering universal social good through a continuous cycle of engagement, interaction and empowerment.

At a time of unprecedented interest in social action globally, ImpactWayv provides the social media network solution that addresses the convergence of three major trends in society:

  • People’s hunger for greater purpose and meaning in all aspects of life – family, friends, social interaction, employment, consumer relationships, investing, donating and volunteering.
  • Businesses’ imperative to demonstrate to all stakeholders and the world their social good efforts.
  • Nonprofits’ pressing need for global connectivity and adoption of private sector business and marketing principles, supporting sustainability and mission achievement.

“ImpactWayv is uniquely positioned for this moment in time,” said George Dolatly, Co-Founder and President of ImpactWayv, Inc. “Our groundbreaking platform creates the opportunity for people, businesses and nonprofits to work together efficiently and effectively on all fronts to maximize social good and positive change.”

ImpactWayv will also feature a digital “Social Impact as a Service” (SIaaS) offering to both businesses and nonprofits to best address emerging social impact trends such as business models that integrate the values and metrics of Environmental, Social & Governance (ESG) criteria, Corporate Social Responsibility (CSR) and the United Nations Sustainable Development Goals (SDGs). This will allow ImpactWayv to provide advisory and support services through a global team of social impact sector leaders, experts and experienced professionals.

“Our current climate has demonstrated just how motivated people are to come together to foster positive social change,” said Benji Bernstein, Co-Founder and Chief Technology Officer of ImpactWayv, Inc. “The time is now for a new digital ecosystem that meets this critical moment – a social media network created to unite and empower people, businesses and nonprofits for greater collective impact, via a continuous cycle of social good. ImpactWayv is that platform, a breakthrough force for good.”

About ImpactWayv, Inc.

ImpactWayv, Inc. is a social impact media and technology company, consisting of thought leaders and doers from across the business, nonprofit and technology sectors. ImpactWayv was created to disrupt and transform the worlds of business and philanthropy through technology – to advance universal social good. For more information or to be added to the ImpactWayv user list, please visit: www.ImpactWayv.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye